Lantheus (NASDAQ:LNTH) Releases FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $6.65-6.70 for the period, compared to the consensus EPS estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LNTH. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JMP Securities lowered their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday. Truist Financial reissued a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday. Finally, Leerink Partners raised their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Trading Down 0.9 %

Shares of NASDAQ:LNTH traded down $0.82 on Friday, hitting $87.50. 1,617,957 shares of the company’s stock were exchanged, compared to its average volume of 993,185. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock has a market capitalization of $6.08 billion, a price-to-earnings ratio of 14.66 and a beta of 0.51. The business’s 50 day simple moving average is $107.71 and its two-hundred day simple moving average is $95.52. Lantheus has a 12 month low of $50.20 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $378.73 million during the quarter, compared to analyst estimates of $373.58 million. Analysts anticipate that Lantheus will post 5.99 EPS for the current fiscal year.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.